CoChat

Effects of anti-TGF-β type II receptor antibody on experimental glomerulonephritis

Open access
Kasuga, Hirotake, Ito, Yasuhiko, Sakamoto, Shinji, Kawachi, Hiroshi, Shimizu, Fujio, Yuzawa, Yukio, Matsuo, Seiichi · 2001 · Kidney International
Cited by 56

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Effects of anti-TGF-β type II receptor antibody on experimental glomerulonephritis Background Renal fibrosis, characterized by the accumulation of extracellular matrix (ECM), is a common histopathological feature of progressive renal disease of diverse etiology. Interaction between transforming growth factor-β (TGF-β) and TGF-β type II receptor (TGF-βIIR) may play an important role in the ongoing fibrotic process. TGF-βIIR and TGF-β have been reported to be up-regulated in human glomerulopathies. In order to block the TGF-β system, many studies have inhibited TGF-β itself, but not its receptors. Our study explored the effects of fully human monoclonal antibody against TGF-βIIR (hTGF-βIIRAb) on experimental proliferative glomerulonephritis. Methods hTGF-βIIRAb was generated from Xenomice. The expression of TGF-βIIR was studied by immunohistochemistry in normal and anti-Thy-1 nephritis rats. hTGF-βIIRAb or control Ab was injected intraperitoneally at day 0 and day 4 of anti-Thy-1 nephritis, and rats were sacrificed at day 7. Effects of hTGF-βIIRAb were assessed by histological and immunopathological measurements. Results The specificity of hTGF-βIIRAb was confirmed by ELISA and Western blot analysis. By immunostaining, TGF-βIIR expression was up-regulated in the proliferative lesions of anti-Thy-1 nephritis at day 7. In the hTGF-βIIRAb-treated group, the extent of mesangial expansion was less than that in the control group. By immunohistology, α-smooth muscle actin, fibronectin-EDA, and type I collagen were significantly reduced in the hTGF-βIIRAb-treated group. Conclusions Anti-TGF-βIIR antibody ameliorated ECM accumulation in anti-Thy-1 nephritis. Our data suggest that TGF-βIIR may be one of the therapeutic targets, and that fully human monoclonal antibody against TGF-βIIR may have a new therapeutic potential for renal fibrosis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1046/j.1523-1755.2001.00990.x

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 56

Metadata

Authors
Kasuga, H., Ito, Y., Sakamoto, S., Kawachi, H., Shimizu, F., Yuzawa, Y., & Matsuo, S.
Venue
Kidney International
Publisher
Elsevier BV
Published
2001-11
Volume
60
Issue
5
Pages
1745-1755
ISSN
0085-2538 (ISSN-L)
OpenAlex
W2146999184
Cited by
56
References
1
FWCI
2.46
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of anti-TGF-β type II receptor antibody on experimental glomerulonephritis. https://app.cochat.ai/papers/10.1046/j.1523-1755.2001.00990.x
The paper
Kasuga, H., Ito, Y., Sakamoto, S., Kawachi, H., Shimizu, F., Yuzawa, Y., & Matsuo, S. (2001). Effects of anti-TGF-β type II receptor antibody on experimental glomerulonephritis. Kidney International. https://doi.org/10.1046/j.1523-1755.2001.00990.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.